$ICCM
Icecure Medical Ltd Stock $iccm

$iccm Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024029586 Filed on April 03, 2024

Income Statement

Concept	2023 Q4	2023	2022
Revenue	$1.255M	$3.229M	$3.085M
YoY Change	33.65%	4.67%	-25.45%
Cost Of Revenue	$686.0K	$1.929M	$1.640M
YoY Change	-94.94%	17.62%	-15.59%
Gross Profit	$569.0K	$1.300M	$1.445M
YoY Change	23.43%	-10.03%	-34.17%
Gross Profit Margin	45.34%	40.26%	46.84%
Selling, General & Admin	$2.101M	$8.603M	$735.0K
YoY Change	-2.55%	1070.48%	-87.84%
% of Gross Profit	369.24%	661.77%	50.87%
Research & Development	$1.883M	$8.273M	$9.123M
YoY Change	-15.82%	-9.32%	55.23%
% of Gross Profit	330.93%	636.38%	631.35%
Depreciation & Amortization	$83.00K	$323.0K	$248.0K
YoY Change	12.16%	30.24%	95.28%
% of Gross Profit	14.59%	24.85%	17.16%
Operating Expenses	$3.984M	$16.88M	$9.858M
YoY Change	-9.31%	71.19%	-17.29%
Operating Profit	-$3.415M	-$15.58M	-$16.74M
YoY Change	-13.15%	-6.95%	72.14%
Interest Expense	$420.0K	$924.0K	-$239.0K
YoY Change	-2200.0%	-486.61%	39.77%
% of Operating Profit
Other Income/Expense, Net		$924.0K	-$239.0K
YoY Change		-486.61%	39.77%
Pretax Income	-$2.995M	-$14.65M	-$16.98M
YoY Change	-24.22%	-13.7%	71.58%
Income Tax
% Of Pretax Income
Net Earnings	-$2.995M	-$14.65M	-$16.98M
YoY Change	-24.22%	-13.7%	71.58%
Net Earnings / Revenue	-238.65%	-453.76%	-550.34%
Basic Earnings Per Share		$0.32	$0.46
Diluted Earnings Per Share	-$0.07	-$0.32	$0.46
COMMON SHARES
Basic Shares Outstanding	45.73M shares	45.64M shares	37.02M shares
Diluted Shares Outstanding		45.64M shares	37.02M shares

Balance Sheet

Concept	2023 Q4	2023	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.06M	$11.06M	$23.66M
YoY Change	-53.24%	-53.24%	-7.66%
Cash & Equivalents	$11.06M	$11.06M	$23.66M
Short-Term Investments
Other Short-Term Assets	$744.0K	$630.0K	$1.536M
YoY Change	-51.56%	-58.98%	-32.93%
Inventory	$2.275M	$2.275M	$2.857M
Prepaid Expenses
Receivables	$103.0K	$103.0K	$78.00K
Other Receivables	$0.00	$114.0K	$0.00
Total Short-Term Assets	$14.18M	$14.18M	$28.13M
YoY Change	-49.58%	-49.58%	-7.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.192M	$2.192M	$2.024M
YoY Change	61.65%	8.3%	24.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$34.00K	$34.00K	$34.00K
YoY Change	0.0%	0.0%	-89.79%
Total Long-Term Assets	$2.226M	$2.226M	$2.058M
YoY Change	8.16%	8.16%	5.05%
TOTAL ASSETS
Total Short-Term Assets	$14.18M	$14.18M	$28.13M
Total Long-Term Assets	$2.226M	$2.226M	$2.058M
Total Assets	$16.41M	$16.41M	$30.19M
YoY Change	-45.64%	-45.64%	-6.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$502.0K	$502.0K	$714.0K
YoY Change	-29.69%	-29.69%	-18.96%
Accrued Expenses	$223.0K	$2.505M	$2.375M
YoY Change	33.53%	5.47%	33.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.871M	$3.871M	$4.336M
YoY Change	-10.72%	-10.72%	7.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$376.0K	$376.0K	$430.0K
YoY Change	-12.56%	-12.56%	-67.0%
Total Long-Term Liabilities	$376.0K	$376.0K	$430.0K
YoY Change	-12.56%	-12.56%	-67.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.871M	$3.871M	$4.336M
Total Long-Term Liabilities	$376.0K	$376.0K	$430.0K
Total Liabilities	$4.247M	$4.247M	$4.766M
YoY Change	-10.89%	-10.89%	-10.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$90.06M
YoY Change	19.43%
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.16M	$12.16M	$25.42M
YoY Change
Total Liabilities & Shareholders Equity	$16.41M	$16.41M	$30.19M
YoY Change	-45.64%	-45.64%	-6.48%

Cashflow Statement

Concept	2023 Q4	2023	2022
OPERATING ACTIVITIES
Net Income	-$2.995M	-$14.65M	-$16.98M
YoY Change	-24.22%	-13.7%	71.58%
Depreciation, Depletion And Amortization	$83.00K	$323.0K	$248.0K
YoY Change	12.16%	30.24%	95.28%
Cash From Operating Activities	-$2.644M	-$12.52M	-$14.29M
YoY Change	-35.95%	-12.39%	13.38%
INVESTING ACTIVITIES
Capital Expenditures	$81.00K	$480.0K	$891.0K
YoY Change	-19.0%	-46.13%	-267.17%
Acquisitions
YoY Change
Other Investing Activities	$9.136M	-$233.0K	$0.00
YoY Change	414.41%		-100.0%
Cash From Investing Activities	$9.055M	-$713.0K	-$891.0K
YoY Change	440.27%	-19.98%	-123.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$68.00K	$83.00K	$13.57M
YoY Change		-99.39%	-56.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	68.00K	83.00K	$13.58M
YoY Change	-99.5%	-99.39%	-56.05%
NET CHANGE
Cash From Operating Activities	-2.644M	-12.52M	-$14.29M
Cash From Investing Activities	9.055M	-713.0K	-$891.0K
Cash From Financing Activities	68.00K	83.00K	$13.58M
Net Change In Cash	6.479M	-13.15M	-$1.606M
YoY Change	-41.76%	718.87%	-107.27%
FREE CASH FLOW
Cash From Operating Activities	-$2.644M	-$12.52M	-$14.29M
Capital Expenditures	$81.00K	$480.0K	$891.0K
Free Cash Flow	-$2.725M	-$13.00M	-$15.18M
YoY Change	-35.55%	-14.37%	25.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.35
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.46
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37016631	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45638030	shares
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40753
CY2023	dei	Entity Registrant Name EntityRegistrantName	ICECURE MEDICAL LTD.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	7 Ha’Eshel St
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	PO Box 3163
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Caesarea
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	3079504
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Security12b Title Security12bTitle	Ordinary Shares, no par value
CY2023	dei	Trading Symbol TradingSymbol	ICCM
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45729684	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1197
CY2023	dei	Auditor Name AuditorName	Brightman Almagor Zohar & Co.
CY2023	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10533000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23659000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	529000	usd
CY2022Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	296000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	103000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	78000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2275000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2857000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	744000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1240000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	14184000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	28130000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	679000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	668000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1513000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1356000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	34000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	34000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2226000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2058000	usd
CY2023Q4	us-gaap	Assets Assets	16410000	usd
CY2022Q4	us-gaap	Assets Assets	30188000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	502000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	714000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	223000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	167000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3146000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3455000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3871000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4336000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	376000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	430000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	376000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	430000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45729684	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45729684	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45623434	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45623434	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102224000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	100831000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90061000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75409000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12163000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	25422000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16410000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30188000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3229000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3085000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4138000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1929000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	1640000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	1943000	usd
CY2023	us-gaap	Gross Profit GrossProfit	1300000	usd
CY2022	us-gaap	Gross Profit GrossProfit	1445000	usd
CY2021	us-gaap	Gross Profit GrossProfit	2195000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8273000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9123000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5877000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4437000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3204000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1917000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4166000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5857000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4125000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-15576000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-16739000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-9724000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	924000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-239000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-171000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14652000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16978000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9895000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.35
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45638030	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37016631	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28548676	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5648000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	14586000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12400000	usd
CY2021	icm	Issuance Of Prefunded Warrant IssuanceOfPrefundedWarrant	3566000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	337000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	316000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9895000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	26958000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13569000	usd
CY2022	icm	Pre Funded Warrants Exercised PreFundedWarrantsExercised	1000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1865000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16978000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	25422000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	28000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	83000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1282000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14652000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12163000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14652000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16978000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9895000	usd
CY2023	us-gaap	Depreciation Depreciation	323000	usd
CY2022	us-gaap	Depreciation Depreciation	248000	usd
CY2021	us-gaap	Depreciation Depreciation	127000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1310000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1865000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	316000	usd
CY2023	icm	Exchange Rate Changes In Cash And Cash Equivalents And Deposit ExchangeRateChangesInCashAndCashEquivalentsAndDeposit	25000	usd
CY2022	icm	Exchange Rate Changes In Cash And Cash Equivalents And Deposit ExchangeRateChangesInCashAndCashEquivalentsAndDeposit	-359000	usd
CY2021	icm	Exchange Rate Changes In Cash And Cash Equivalents And Deposit ExchangeRateChangesInCashAndCashEquivalentsAndDeposit	-5000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	25000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-378000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	362000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-582000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	902000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	891000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-496000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1050000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2030000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-182000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-245000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	607000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-212000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-167000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	236000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-191000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-312000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	577000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-309000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	540000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	60000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-618000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-141000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12521000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14292000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12605000	usd
CY2023	icm	Investment Of Deposits InvestmentOfDeposits	-529000	usd
CY2021	icm	Investment Of Deposits InvestmentOfDeposits	4621000	usd
CY2023	icm	Realization Ofinvestment In Restricted Deposits RealizationOfinvestmentInRestrictedDeposits	-296000	usd
CY2021	icm	Realization Ofinvestment In Restricted Deposits RealizationOfinvestmentInRestrictedDeposits	296000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	480000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	891000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	533000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-713000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-891000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3792000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13569000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14586000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	6000	usd
CY2021	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	15966000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	337000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13577000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30889000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-13151000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1606000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	22076000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23659000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25621000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3502000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-356000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	43000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10533000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23659000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25621000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	193000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - GENERAL</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of the Company:</b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IceCure Medical Ltd. (“IceCure Medical Ltd.”, the “Company”, “we” or “our”) is a medical device Company incorporated in Israel.</span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 2, 2011, we became a public company in Israel and our ordinary shares were listed for trade on the Tel Aviv Stock Exchange (“TASE”). On August 26, 2021, our ordinary shares were listed for trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ICCM.” On July 24, 2023, we delisted our Ordinary Shares from the TASE.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since its establishment, IceCure Medical Ltd., and its wholly-owned subsidiaries, IceCure Medical Inc. in the United States (the “U.S. Subsidiary”), IceCure Medical HK Limited in Hong Kong (the “Hong Kong Subsidiary”) and IceCure (Shanghai) MedTech Co., Ltd. in China (the “Chinese Subsidiary”, and together with the Company, U.S. Subsidiary and Hong Kong Subsidiary, the “Group”), have been engaged in the research, development and commercialization of minimally invasive medical devices for cryoablation (freezing) of tumors in the human body, using its propriety liquid nitrogen Cryoablation technology, as an alternative to surgical intervention to remove the tumor. The Company received regulatory approvals for marketing its products in the United States, Europe and other territories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. Subsidiary was established on April 6, 2011 in the State of Delaware and is engaged in business development, marketing, clinical trial management and sale of the Company’s products in the United States. The Hong Kong Subsidiary was established on September 26, 2018 and commenced its activity in 2021. The Chinese Subsidiary was established on July 14, 2020 and is wholly owned by the Hong Kong Subsidiary. The Chinese Subsidiary in China commenced its operation on January 1, 2021 and is engaged in business development, obtaining regulatory approvals and marketing activities for the Company’s products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to commercialize its technology, obtaining regulatory approvals, and developing and obtaining regulatory approval for its next generation systems. In addition, the Group is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements and limited operating history.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk factors:</b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to operate successfully is materially uncertain and our operations are subject to significant risks inherent in a developing business enterprise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to continue our commercialization efforts and to achieve a level of sales adequate to support the Company’s cost structure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need to raise additional funds to meet our anticipated expenses so that we can execute our business plan. We expect to incur substantial and increasing net losses for the foreseeable future as we increase our spending to execute our development programs.</span></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount of financing required will depend on many factors, including our research and development costs, our clinical trials, our commercialization efforts, and other working capital requirements. Our ability to access capital markets or to secure partnerships is mainly dependent on the progress of our research and development, our clinical trials, regulatory approval of our products, and our success in the commercialization of our products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern:</b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company has accumulated losses of $90,061. In the year ended December 31, 2023, the Company generated losses of $14,652, and negative cash flows from operating activities of $12,521.</span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">To date, management expects the Company to continue to generate substantial operating losses and fund its operations primarily through utilization of its current financial resources, sales of its products, and additional raises of capital. As of March 31, 2024, the Company’s cash, cash equivalents and short-term deposits were approximately $11 million.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan to continue as a going concern includes raising funds from existing shareholders and/or new investors. However, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to successfully complete the development of, and to commercialize, its products. These financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.</span></p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90061000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14652000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12521000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates:</b></span></td> </tr></table><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Inventory Net InventoryNet	2275000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2857000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	187000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	646000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	187000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	646000	usd
CY2023	icm	Severance Percentage Of Monthly Salary SeverancePercentageOfMonthlySalary	0.0833	pure
CY2023	icm	Tax Benefit Largest Amount TaxBenefitLargestAmount	0.50	pure
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>P.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of credit risk:</b></span></td> </tr></table><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, deposit and trade accounts receivables.</span></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The management believes that the financial institutions that hold the Company’s investments are corporations with high credit standing. Accordingly, management believes that low credit risk exists with respect to these financial investments.</span></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s trade receivables are derived from sales to customers located primarily in the Americas, APAC, and Europe. The Company performs ongoing credit evaluations of its customers’ financial condition. Under certain circumstances, the Company may require advance payments.</span></p>
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1391000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1566000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	316000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	356000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	568000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	935000	usd
CY2023Q4	us-gaap	Area Of Land AreaOfLand	879	sqm
CY2023	icm	Bank Guarantee BankGuarantee	20000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	679000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	668000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	599000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	597000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	246000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	242000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	247000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	276000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	257000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	145000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	678000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	79000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	599000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M21D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2732000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2262000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1219000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	906000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1513000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1356000	usd
CY2023	us-gaap	Depreciation Depreciation	323000	usd
CY2022	us-gaap	Depreciation Depreciation	248000	usd
CY2021	us-gaap	Depreciation Depreciation	127000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	187000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	646000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	47000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	47000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1362000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1580000	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	630000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	554000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	920000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	628000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3146000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3455000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	2084000	usd
CY2023Q4	us-gaap	Deposits Deposits	71000	ils
CY2023Q4	us-gaap	Deposits Deposits	20000	usd
CY2021Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	5000000	ils
CY2021Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	1378000	usd
CY2021Q1	icm	Total Share Purchase Agreement TotalSharePurchaseAgreement	7500000	usd
CY2021Q1	us-gaap	Investment Income Net InvestmentIncomeNet	15000000	usd
CY2021Q1	icm	Total Ordinary Shares TotalOrdinaryShares	11485697	shares
CY2021Q1	us-gaap	Shares Acquired Weighted Average Discount To Net Assets Percentage SharesAcquiredWeightedAverageDiscountToNetAssetsPercentage	0.20	pure
CY2021Q1	us-gaap	Amount Of Regulatory Assistance Received1 AmountOfRegulatoryAssistanceReceived1	9000000	usd
CY2021Q1	us-gaap	Investment Owned Percent Of Net Assets InvestmentOwnedPercentOfNetAssets	0.60	pure
CY2021Q1	us-gaap	Statutory Accounting Practices Dividends Paid With Approval Of Regulatory Agency StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency	6000000	usd
CY2021Q2	us-gaap	Amount Of Regulatory Assistance Received1 AmountOfRegulatoryAssistanceReceived1	6000000	usd
CY2021Q4	icm	Gross Raised Amount GrossRaisedAmount	16994000	usd
CY2021Q4	icm	Ordinary Shares OrdinaryShares	3892152	shares
CY2021Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	578325	shares
CY2021Q4	icm	Proceeds From Fee Received ProceedsFromFeeReceived	15966000	usd
CY2022Q2	us-gaap	Shares Issued SharesIssued	1034000	shares
CY2022Q2	icm	Ordinary Shares OrdinaryShares	1034000	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	21000	shares
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14500000	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8787880	shares
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.65
CY2022Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	13569000	usd
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	Accordingly, all option numbers, share numbers, share prices, exercise prices and losses per share were adjusted within these consolidated financial statements, on a retroactive basis, to reflect this 8-for-1 reverse stock split.
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	244926	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	92000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.12
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8929	shares
CY2021Q2	icm	Options Number Of Underlying Shares OptionsNumberOfUnderlyingShares	8929	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.76
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1720660	shares
CY2022Q1	icm	Options Number Of Underlying Shares OptionsNumberOfUnderlyingShares	1720660	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.61
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	30434	shares
CY2022Q1	icm	Options Number Of Underlying Shares OptionsNumberOfUnderlyingShares	30434	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.73
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	55222	shares
CY2022Q3	icm	Options Number Of Underlying Shares OptionsNumberOfUnderlyingShares	55222	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.78
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1107940	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1107940	shares
CY2023Q1	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	41412	shares
CY2023Q1	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	1.37
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P4Y
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50000000	usd
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1310000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1865000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	316000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1229000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y7M6D
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3229000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3085000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4138000	usd
CY2023	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation	On June 12 2022, the Chinese Subsidiary signed an exclusive sale and distribution agreement for the Systems and disposables with Shanghai Medtronic Zhikang Medical Devices Co. Ltd. (“Shanghai Medtronic Zhikang”) and Turing for an initial term of 36 months, with a minimum purchase target of $3.5 million within this term.
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3500000	usd
CY2023	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	In addition, milestones have been set, for which, if met, the Company will receive the following amounts (that were identified by the Company as variable consideration): (1)$250 will be paid to the Company upon the submission of an application for regulatory approval for the products in Japan; (2)$250 will be paid to the Company upon the receipt of regulatory approval in Japan; and (3)$500 will be paid to the Company upon the receipt of approval for medical reimbursement for the procedure in Japan
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	4250000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4000000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4250000	usd
CY2023	us-gaap	Cost Direct Labor CostDirectLabor	551000	usd
CY2022	us-gaap	Cost Direct Labor CostDirectLabor	896000	usd
CY2021	us-gaap	Cost Direct Labor CostDirectLabor	796000	usd
CY2023	us-gaap	Cost Direct Material CostDirectMaterial	905000	usd
CY2022	us-gaap	Cost Direct Material CostDirectMaterial	298000	usd
CY2021	us-gaap	Cost Direct Material CostDirectMaterial	828000	usd
CY2023	us-gaap	Direct Operating Costs DirectOperatingCosts	42000	usd
CY2022	us-gaap	Direct Operating Costs DirectOperatingCosts	48000	usd
CY2021	us-gaap	Direct Operating Costs DirectOperatingCosts	50000	usd
CY2023	icm	Costof Royalties CostofRoyalties	96000	usd
CY2022	icm	Costof Royalties CostofRoyalties	93000	usd
CY2021	icm	Costof Royalties CostofRoyalties	123000	usd
CY2023	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	161000	usd
CY2022	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	111000	usd
CY2021	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	33000	usd
CY2023	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	174000	usd
CY2022	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	194000	usd
CY2021	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	113000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1929000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	1640000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	1943000	usd
CY2023	icm	Researchanddevelopmentpayroll And Related Benefitsincluding Sharebased Compensation ResearchanddevelopmentpayrollAndRelatedBenefitsincludingSharebasedCompensation	5395000	usd
CY2022	icm	Researchanddevelopmentpayroll And Related Benefitsincluding Sharebased Compensation ResearchanddevelopmentpayrollAndRelatedBenefitsincludingSharebasedCompensation	5969000	usd
CY2021	icm	Researchanddevelopmentpayroll And Related Benefitsincluding Sharebased Compensation ResearchanddevelopmentpayrollAndRelatedBenefitsincludingSharebasedCompensation	3748000	usd
CY2023	icm	Raw Materials Subcontracted Work And Consulting RawMaterialsSubcontractedWorkAndConsulting	1593000	usd
CY2022	icm	Raw Materials Subcontracted Work And Consulting RawMaterialsSubcontractedWorkAndConsulting	1742000	usd
CY2021	icm	Raw Materials Subcontracted Work And Consulting RawMaterialsSubcontractedWorkAndConsulting	1440000	usd
CY2023	icm	Clinical Trials ClinicalTrials	436000	usd
CY2022	icm	Clinical Trials ClinicalTrials	495000	usd
CY2021	icm	Clinical Trials ClinicalTrials	200000	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	849000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	917000	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	489000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8273000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9123000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5877000	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2239000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1599000	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1036000	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	987000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	566000	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	215000	usd
CY2023	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	354000	usd
CY2022	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	274000	usd
CY2021	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	126000	usd
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	92000	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	74000	usd
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	60000	usd
CY2023	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	49000	usd
CY2022	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	13000	usd
CY2021	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	60000	usd
CY2023	icm	Conferences Conferences	323000	usd
CY2022	icm	Conferences Conferences	301000	usd
CY2021	icm	Conferences Conferences	93000	usd
CY2023	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	393000	usd
CY2022	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	377000	usd
CY2021	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	327000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4437000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3204000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1917000	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1886000	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	2262000	usd
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1403000	usd
CY2023	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	1966000	usd
CY2022	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	3369000	usd
CY2021	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	2440000	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	284000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	226000	usd
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	282000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4166000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5857000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4125000	usd
CY2023	icm	Income Taxes Description IncomeTaxesDescription	The Chinese subsidiary is subject to a progressive tax rate in China of 2.5% up to taxable income of one million RMB, 5% on taxable income between one million RMB to three million RMB and 25% on taxable income higher than three million RMB, for the year ended December 31, 2023 and 2022.
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18608000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17183000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	145000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	127000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18753000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17310000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18753000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17310000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18753000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	14652000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16952000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	10081000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	26000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-186000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14652000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16978000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9895000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3370000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3905000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2276000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3370000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3905000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2161000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-115000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3229000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3085000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4138000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1513000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1356000	usd
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2023Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.32
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28548676	shares
CY2021	us-gaap	Treasury Stock Retired Par Value Method Amount TreasuryStockRetiredParValueMethodAmount		usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		usd
CY2022	icm	Investment Of Deposits InvestmentOfDeposits		usd
CY2022	icm	Realization Ofinvestment In Restricted Deposits RealizationOfinvestmentInRestrictedDeposits		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans		usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans		usd
CY2023	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments		usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001584371

Files In Submission

Name	View Source	Status
0001213900-24-029586-index-headers.html	Edgar Link	pending
0001213900-24-029586-index.html	Edgar Link	pending
0001213900-24-029586.txt	Edgar Link	pending
0001213900-24-029586-xbrl.zip	Edgar Link	pending
ea0202979-20f_icecure.htm	Edgar Link	pending
ea020297901ex12-1_icecure.htm	Edgar Link	pending
ea020297901ex12-2_icecure.htm	Edgar Link	pending
ea020297901ex13-1_icecure.htm	Edgar Link	pending
ea020297901ex13-2_icecure.htm	Edgar Link	pending
ea020297901ex15-1_icecure.htm	Edgar Link	pending
ea020297901ex2-1_icecure.htm	Edgar Link	pending
ea020297901ex4-9_icecure.htm	Edgar Link	pending
ea020297901ex97-1_icecure.htm	Edgar Link	pending
ex4-9_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
fin_002.jpg	Edgar Link	pending
icm-20231231.xsd	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
icm-20231231_def.xml	Edgar Link	unprocessable
icm-20231231_pre.xml	Edgar Link	unprocessable
icm-20231231_lab.xml	Edgar Link	unprocessable
ea0202979-20f_icecure_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
icm-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICCM
Icecure Medical Ltd Stock $iccm

2023 Q4 Form 20-F Financial Statement

#000121390024029586 Filed on April 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCM Icecure Medical Ltd Stock $iccm

2023 Q4 Form 20-F Financial Statement

#000121390024029586 Filed on April 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCM
Icecure Medical Ltd Stock $iccm